SEC Form 4Coverage since Jun 1, 2026
$TNGX insider trading
Over the last 12 months, Tango Therapeutics insiders reported no purchases and 4 sales totaling $2.2M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $2.2M 4 events
- Events · 12m
- 4 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $TNGX · 12Mvia TradingView
Top insiders · 12m
Crystal AdamPresident, R&D4× · $2.2M
All insider trades
4 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | Crystal AdamPresident, R&D · O | ▼ Sale | 27,000 | $27.24 | $736K | -18.9% | plan · 2 tranches |
| Jul 1, 2026 | Crystal AdamPresident, R&D · O | ▼ Sale | 27,000 | $29.59 | $799K | -18.9% | plan · 2 tranches |
| Jun 1, 2026 | Crystal AdamPresident, R&D · O | ▼ Sale | 20,860 | $23.06 | $481K | -15.3% | plan |
| Jun 1, 2026 | Crystal AdamPresident, R&D · O | ▼ Sale | 6,140 | $22.25 | $137K | -4.3% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $TNGX feed.